A detailed history of Royal Fund Management, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Royal Fund Management, LLC holds 48,957 shares of ABBV stock, worth $8.81 Million. This represents 0.58% of its overall portfolio holdings.

Number of Shares
48,957
Previous 46,665 4.91%
Holding current value
$8.81 Million
Previous $8 Million 20.8%
% of portfolio
0.58%
Previous 0.85%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$163.84 - $199.33 $375,521 - $456,864
2,292 Added 4.91%
48,957 $9.67 Million
Q2 2024

Jul 18, 2024

SELL
$154.79 - $180.76 $98,756 - $115,324
-638 Reduced 1.35%
46,665 $8 Million
Q1 2024

Apr 11, 2024

SELL
$159.82 - $182.1 $96,371 - $109,806
-603 Reduced 1.26%
47,303 $8.61 Million
Q4 2023

Feb 06, 2024

SELL
$137.6 - $154.97 $27,382 - $30,839
-199 Reduced 0.41%
47,906 $7.42 Million
Q3 2023

Oct 17, 2023

SELL
$133.59 - $154.65 $177,140 - $205,065
-1,326 Reduced 2.68%
48,105 $7.17 Million
Q2 2023

Jul 12, 2023

BUY
$132.51 - $164.9 $530,702 - $660,424
4,005 Added 8.82%
49,431 $6.66 Million
Q1 2023

Apr 10, 2023

BUY
$144.61 - $166.54 $429,057 - $494,124
2,967 Added 6.99%
45,426 $7.24 Million
Q4 2022

Jan 20, 2023

BUY
$138.31 - $165.87 $460,157 - $551,849
3,327 Added 8.5%
42,459 $0
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $278,351 - $319,250
-2,074 Reduced 5.03%
39,132 $5.25 Million
Q2 2022

Jul 28, 2022

BUY
$137.62 - $174.96 $260,652 - $331,374
1,894 Added 4.82%
41,206 $6.31 Million
Q1 2022

May 13, 2022

SELL
$131.98 - $163.75 $129,472 - $160,638
-981 Reduced 2.43%
39,312 $6.37 Million
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $53,392 - $67,557
497 Added 1.25%
40,293 $5.46 Million
Q3 2021

Oct 20, 2021

BUY
$106.4 - $120.78 $77,459 - $87,927
728 Added 1.86%
39,796 $4.29 Million
Q2 2021

Jul 26, 2021

SELL
$105.21 - $117.21 $88,271 - $98,339
-839 Reduced 2.1%
39,068 $4.4 Million
Q1 2021

Apr 29, 2021

BUY
$102.3 - $112.62 $166,646 - $183,457
1,629 Added 4.26%
39,907 $4.32 Million
Q4 2020

Feb 02, 2021

SELL
$80.49 - $108.67 $193,739 - $261,568
-2,407 Reduced 5.92%
38,278 $4.1 Million
Q3 2020

Oct 13, 2020

SELL
$85.91 - $100.83 $387,969 - $455,348
-4,516 Reduced 9.99%
40,685 $3.56 Million
Q2 2020

Aug 06, 2020

BUY
$73.37 - $98.18 $645,289 - $863,493
8,795 Added 24.16%
45,201 $4.44 Million
Q1 2020

May 08, 2020

SELL
$64.5 - $97.79 $3.7 Million - $5.6 Million
-57,288 Reduced 61.14%
36,406 $2.77 Million
Q4 2019

May 11, 2020

SELL
$72.13 - $90.25 $726,998 - $909,629
-10,079 Reduced 9.71%
93,694 $8.3 Million
Q3 2019

May 08, 2020

BUY
$62.98 - $75.72 $1.81 Million - $2.18 Million
28,789 Added 38.39%
103,773 $7.86 Million
Q2 2019

May 08, 2020

SELL
$65.7 - $83.98 $365,423 - $467,096
-5,562 Reduced 6.91%
74,984 $5.45 Million
Q1 2019

May 11, 2020

SELL
$77.14 - $90.79 $131,292 - $154,524
-1,702 Reduced 2.07%
80,546 $6.49 Million
Q4 2018

May 07, 2020

SELL
$77.85 - $96.01 $5.24 Million - $6.46 Million
-67,291 Reduced 45.0%
82,248 $7.58 Million
Q3 2018

May 07, 2020

SELL
$88.91 - $98.84 $318,208 - $353,748
-3,579 Reduced 2.34%
149,539 $14.1 Million
Q2 2018

May 07, 2020

BUY
$89.78 - $106.23 $1.54 Million - $1.82 Million
17,160 Added 12.62%
153,118 $14.2 Million
Q1 2018

May 07, 2020

SELL
$92.01 - $123.21 $2.1 Million - $2.82 Million
-22,870 Reduced 14.4%
135,958 $12.9 Million
Q4 2017

May 07, 2020

SELL
$89.56 - $98.21 $390,660 - $428,392
-4,362 Reduced 2.67%
158,828 $15.4 Million
Q3 2017

May 07, 2020

SELL
$69.85 - $89.22 $256,908 - $328,151
-3,678 Reduced 2.2%
163,190 $14.5 Million
Q2 2017

May 07, 2020

BUY
N/A
6,198 Added 3.86%
166,868 $12.1 Million
Q1 2017

May 07, 2020

BUY
N/A
19,286 Added 13.64%
160,670 $10.5 Million
Q4 2016

May 07, 2020

BUY
N/A
141,384
141,384 $8.85 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Royal Fund Management, LLC Portfolio

Follow Royal Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Royal Fund Management, LLC with notifications on news.